Interleukin-6 signalling regulates vascular endothelial growth factor-C synthesis and lymphangiogenesis in human oral squamous cell carcinoma

Journal of Pathology

Volumn 225, Issue 1, 2011, Pages 142-150

  Shinriki, Satoru ^a   Jono, Hirofumi ^a   Ueda, Mitsuharu ^a   Ota, Kazutoshi ^b   Ota, Tomoko ^b   Sueyoshi, Takanao ^b   Oike, Yuichi ^b   Ibusuki, Mutsuko ^b   Hiraki, Akimitsu ^b   Nakayama, Hideki ^b   Shinohara, Masanori ^b   Ando, Yukio ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

Author keywords

interleukin 6; interleukin 6 receptor; lymph node metastasis; lymphangiogenesis; oral squamous cell carcinoma; tocilizumab; vascular endothelial growth factor C

Indexed keywords

INTERLEUKIN 6; INTERLEUKIN 6 ANTIBODY; INTERLEUKIN 6 RECEPTOR; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; TOCILIZUMAB; VASCULOTROPIN C;

AGED; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER PATIENT; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; LYMPH NODE METASTASIS; LYMPHANGIOGENESIS; MAJOR CLINICAL STUDY; MALE; MOUSE; MOUTH CARCINOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; XENOGRAFT;

AGED; ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; DRUG EVALUATION, PRECLINICAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERLEUKIN-6; LYMPHANGIOGENESIS; MALE; MICE; MICE, SCID; MIDDLE AGED; MOUTH NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RNA, MESSENGER; RNA, NEOPLASM; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR C; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79960905472     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2935     Document Type: Article

References (50)

1. Jemal A, Siegel R, Ward E, et al., Cancer statistics, 2006. CA Cancer J Clin 2006; 56: 106-130.
2. Forastiere AA, Goepfert H, Maor M, et al., Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003; 349: 2091-2098. (Pubitemid 37464533)
3. Kowalski LP, Medina JE,. Nodal metastases: predictive factors. Otolaryngol Clin North Am 1998; 31: 621-637. (Pubitemid 28406530)
4. Alitalo K, Tammela T, Petrova TV,. Lymphangiogenesis in development and human disease. Nature 2005; 438: 946-953. (Pubitemid 43093960)
5. Achen MG, Stacker SA,. Tumor lymphangiogenesis and metastatic spread-new players begin to emerge. Int J Cancer 2006; 119: 1755-1760. (Pubitemid 44356830)
6. Beasley NJP, Prevo R, Banerji S, et al., Intratumoral lymphangiogenesis and lymph node metastasis in head and neck cancer. Cancer Res 2002; 62: 1315-1320. (Pubitemid 34407785)
7. Franchi A, Gallo O, Massi D, et al., Tumor lymphangiogenesis in head and neck squamous cell carcinoma: a morphometric study with clinical correlations. Cancer 2004; 101: 973-978. (Pubitemid 39100431)
8. Miyahara M, Tanuma J, Sugihara K, et al., Tumor lymphangiogenesis correlates with lymph node metastasis and clinicopathological parameters in oral squamous cell carcinoma. Cancer 2007; 110: 1287-1294. (Pubitemid 47435600)
9. O-charoenrat P, Rhys-Evans P, Eccles SA,. Expression of vascular endothelial growth factor family members in head and neck squamous cell carcinoma correlates with lymph node metastasis. Cancer 2001; 92: 556-568. (Pubitemid 32735191)
10. Achen MG, McColl BK, Stacker SA,. Focus on lymphangiogenesis in tumor metastasis. Cancer Cell 2005; 7: 121-127. (Pubitemid 40248338)
11. Skobe M, Hawighorst T, Jackson DG, et al., Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat Med 2001; 7: 192-198. (Pubitemid 32148486)
12. Mandoriota SJ, Jussila L, Jeltsch M, et al., Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis. EMBO J 2001; 20: 672-682. (Pubitemid 32167632)
13. Karpanen T, Egeblad M, Karkkainen MJ, et al., Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth. Cancer Res 2001; 61: 1786-1790. (Pubitemid 32691984)
14. Koshikawa K, Yla-Herttuala S, Takahashi T, et al., Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking VEGFR3 signaling. J Natl Cancer Inst 2002; 94: 819-825. (Pubitemid 34705053)
15. Kishimoto T,. Interleukin-6: from basic science to medicine-40 years in immunology. Annu Rev Immunol 2005; 23: 1-21. (Pubitemid 40563163)
16. Trikha M, Corringham R, Klein B, et al., Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. Clin Cancer Res 2003; 9: 4653-4665. (Pubitemid 37323267)
17. Hong DS, Angelo LS, Kurzrock R,. Interleukin-6 and its receptor in cancer: implications for translational therapeutics. Cancer 2007; 110: 1911-1928. (Pubitemid 350036849)
18. Chen Z, Malhotra PS, Thomas GR, et al., Expression of proinflammatory and proangiogenic cytokines in patients with head and neck cancer. Clin Cancer Res 1999; 5: 1369-1379. (Pubitemid 29282941)
19. Duffy SA, Taylor JM, Terrell JE, et al., Interleukin-6 predicts recurrence and survival among head and neck cancer patients. Cancer 2008; 113: 750-757.
20. Shinriki S, Jono H, Ota K, et al., Humanized anti-interleukin-6 receptor antibody suppresses tumor angiogenesis and in vivo growth of human oral squamous cell carcinoma. Clin Cancer Res 2009; 15: 5426-5434.
21. Sato K, Tsuchiya M, Saldanha J, et al., Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth. Cancer Res 1993; 53: 851-856. (Pubitemid 23077873)
22. Mihara M, Kasutani K, Okazaki M, et al., Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family. Int Immunopharmacol 2005; 5: 1731-1740. (Pubitemid 41116745)
23. Venkiteshwaran A,. Tocilizumab. MABS 2009; 1: 432-438.
24. Abramoff MD, Magelhaes PJ, Ram SJ,. Image processing with ImageJ. Biophot Int 2004; 11: 36-42.
25. Molinolo AA, Amornphimoltham P, Squarize CH, et al., Dysregulated molecular networks in head and neck carcinogenesis. Oral Oncol 2009; 45: 324-334.
26. Maula SM, Luukkaa M, Grenman R, et al., Intratumoral lymphatics are essential for the metastatic spread and prognosis in squamous cell carcinomas of the head and neck region. Cancer Res 2003; 63: 1920-1926. (Pubitemid 36460859)
27. Quon H, Liu FF, Cummings BJ,. Potential molecular prognostic markers in head and neck squamous cell carcinomas. Head Neck 2001; 23: 147-159. (Pubitemid 32060666)
28. Kyzas PA, Geleff S, Batistatou A, et al., Evidence for lymphangiogenesis and its prognostic implications in head and neck squamous cell carcinoma. J Pathol 2005; 206: 170-177. (Pubitemid 40754020)
29. Joukov V, Pajusola K, Kaipainen A, et al., A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt-4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J 1996; 15: 290-298. (Pubitemid 26029207)
30. Veikkola T, Jussila L, Makinen T, et al., Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice. EMBO J 2001; 20: 1223-1231. (Pubitemid 32233963)
31. Saharinen P, Tammela T, Karkkainen MJ, et al., Lymphatic vasculature: development, molecular regulation and role in tumor metastasis and inflammation. Trends Immunol 2004; 25: 387-395. (Pubitemid 38780956)
32. Wang YF, Chang SY, Tai SK, et al., Clinical significance of interleukin-6 and interleukin-6 receptor expressions in oral squamous cell carcinoma. Head Neck 2002; 24: 850-858.
33. Riedel F, Zaiss I, Herzog D, et al., Serum levels of interleukin-6 in patients with primary head and neck squamous cell carcinoma. Anticancer Res 2005; 25: 2761-2765.
34. Brideau G, Mäkinen MJ, Elamaa H, et al., Endostatin overexpression inhibits lymphangiogenesis and lymph node metastasis in mice. Cancer Res 2007; 67: 11528-11535.
35. Baluk P, Tammela T, Ator E, et al., Pathogenesis of persistent lymphatic vessel hyperplasia in chronic airway inflammation. J Clin Invest 2005; 115: 247-257. (Pubitemid 40385467)
36. Kataru RP, Jung K, Jang C, et al., Critical role of CD11b macrophages and VEGF in inflammatory lymphangiogenesis, antigen clearance and inflammation resolution. Blood 2009; 113: 5650-5659.
37. Iwata C, Kano MR, Komuro A, et al., Inhibition of cyclo-oxygenase-2 suppresses lymph node metastasis via reduction of lymphangiogenesis. Cancer Res 2007; 67: 10181-10189. (Pubitemid 350070790)
38. Mantovani A, Allavena P, Sica A, et al., Cancer-related inflammation. Nature 2008; 454: 436-444.
39. Hirano T, Nakajima K, Hibi M,. Signaling mechanisms through gp130: a model of the cytokine system. Cytokine Growth Factor Rev 1997; 8: 241-252. (Pubitemid 28202436)
40. Tsutsui S, Matsuyama A, Yamamoto M, et al., The Akt expression correlates with the VEGF-A and -C expression as well as the microvessel and lymphatic vessel density in breast cancer. Oncol Rep 2010; 23: 621-630.
41. Lim J, Kim JH, Paeng JY, et al., Prognostic value of activated Akt expression in oral squamous cell carcinoma. J Clin Pathol 2005; 58: 1199-1205. (Pubitemid 41566467)
42. Tang Y, Zhang D, Fallavollita L, et al., Vascular endothelial growth factor C expression and lymph node metastasis are regulated by the type I insulin-like growth factor receptor. Cancer Res 2003; 63: 1166-1171. (Pubitemid 36348689)
43. Kobayashi S, Kishimoto T, Kamata S, et al., Rapamycin, a specific inhibitor of the mammalian target of rapamycin, suppresses lymphangiogenesis and lymphatic metastasis. Cancer Sci 2007; 98: 726-733. (Pubitemid 46563450)
44. He Y, Kozaki K, Karpanen T, et al., Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling. J Natl Cancer Inst 2005; 94: 819-825.
45. Burton JB, Priceman SJ, Sung JL, et al., Suppression of prostate cancer nodal and systemic metastasis by blockade of the lymphangiogenic axis. Cancer Res 2008; 68: 7828-7837.
46. Bromberg J, Wang TC,. Inflammation and cancer: IL-6 and STAT3 complete the link. Cancer Cell 2009; 15: 79-80.
47. Suzuki H, Yasukawa K, Saito T, et al., Serum soluble interleukin-6 receptor in MRL/lpr mice is elevated with age and mediates the interleukin-6 signal. Eur J Immunol 1993; 23: 1078-1082. (Pubitemid 23120169)
48. Kerjaschki D,. The crucial role of macrophages in lymphangiogenesis. J Clin Invest 2005; 115: 2316-2319. (Pubitemid 41266190)
49. Su JL, Yen CJ, Chen PS, et al., The role of the VEGF-C/VEGFR-3 axis in cancer progression. Br J Cancer 2007; 96: 541-545.
50. Matsuura M, Onimaru M, Yonemitsu Y, et al., Autocrine loop between vascular endothelial growth factor (VEGF)-C and VEGF receptor-3 positively regulates tumor-associated lymphangiogenesis in oral squamoid cancer cells. Am J Pathol 2009; 175: 1709-1721.